Avelas Biosciences Gains $7.65M For Tumor Visualization
San Diego-based Avelas Biosciences has raised $7.65M in a Series A funding round, which it says will go towards clinical studies for its technology for real-time tumor visualization. The funding came from Avalon Ventures. Avelas is developing technology for visualizing cancerous lymph nodes in breast cancer patients. The firm's technology is based on technology developed by Nobel Prize winner Roger Tsien, Ph.D. The firm's CEO is currently Jay Lichter, who is also a Managing Director at Avalon Ventures.
posted on Thursday, December 6, 2012 (Link to more information)

Related companies:
Avelas Biosciences

Related stories:
> Avelas Biosciences Finds $7.4M
> Avelas Biosciences Raises $20M
> Avelas Biosciences Raises $6.85M
> Gen-Probe Invests $50M In Pacific Biosciences
> USC Spinout Gains From $3.5M Award Home